| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | RPRX | Class A Ordinary Shares | Sale | -$6.47M | -155K | -0.7% | $41.72 | 21.9M | Sep 16, 2022 | See Footnotes | F1, F2, F3, F4 |
| transaction | RPRX | Class A Ordinary Shares | Sale | -$9.64M | -232K | -1.06% | $41.50 | 21.7M | Sep 19, 2022 | See Footnotes | F1, F2, F3, F5 |
| Id | Content |
|---|---|
| F1 | Reflects securities held directly by GG 1978 SICAF SIF S.A. - GG Strategic ("GG Strategic"). |
| F2 | GG Strategic is a sub-fund managed and administered by GG 1978 SICAF S.A. ("GG 1978 SICAF"). A board of directors consisting of Giammaria Giuliani, Achille G. Severgnini, Marco Sterzi and Franco Toscano has voting and dispositive power over the securities managed by GG 1978 SICAF. Each member of the board disclaims beneficial ownership over such shares. GG 1978 SICAF is owned by the GG Trust, of which Giammaria Giuliani is the beneficiary. The GG Trust is the 100% economic owner of the shares held by GG Strategic. Giammaria Giuliani disclaims beneficial ownership over the shares beneficially owned by GG Strategic. The trustee of the GG Trust is GISEV Trustees Limited. The protector of the GG Trust is Achille G. Severgnini, who has the power to remove and replace the trustee of the GG Trust. |
| F3 | Each of the Reporting Persons may be deemed to beneficially own the securities reported herein directly or indirectly controlled by it or him, but each (other than the direct holder to the extent of its direct holdings) disclaims beneficial ownership of such securities, except to the extent of such Reporting Person's pecuniary interest therein. The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the Reporting Persons are the beneficial owners of any securities reported herein or are subject to Section 16. |
| F4 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.32 to $42.06 per share, inclusive. The Reporting Persons undertake to provide to Royalty Pharma plc, any security holder of Royalty Pharma plc, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F5 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.99 to $41.77 per share, inclusive. The Reporting Persons undertake to provide to Royalty Pharma plc, any security holder of Royalty Pharma plc, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |